Physician profile
Alejandro Garcia
NPI 1578195756
$1,567.04
in general payments reported to CMS, 2019-2025
19 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $126 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.15 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $338.53 | 2025 | |
| Novo Nordisk INC | $195.50 | 2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $145.50 | 2025 | Mounjaro, Kisunla, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.43 | 2025 | Caplyta |
| Amgen INC. | $101.43 | 2024-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $98.74 | 2025 | |
| Corcept Therapeutics | $71.59 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $68.19 | 2024-2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.17 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.66 | 2025 | Xifaxan |
| Insulet Corporation | $51.81 | 2025 | Omnipod |
| Intra-Sana Laboratories | $47.46 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Teva Pharmaceuticals USA, INC. | $45.24 | 2025 | Austedo Xr |
| Inspire Medical Systems, INC. | $42.04 | 2024 | Inspire |
| Otsuka America Pharmaceutical, INC. | $40.88 | 2024-2025 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $38.84 | 2025 | Rexulti |
| Astellas Pharma US INC | $29.87 | 2025 | Veozah |
| Aimmune Therapeutics, INC. | $15.08 | 2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $14.08 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.